Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Linda Battalagine"'
Autor:
Maureen Caligiuri, Grace L. Williams, Jennifer Castro, Linda Battalagine, Erik Wilker, Lili Yao, Shawn Schiller, Angela Toms, Ping Li, Eneida Pardo, Bradford Graves, Joey Azofeifa, Agustin Chicas, Torsten Herbertz, Maria Lai, Joel Basken, Kenneth W. Wood, Qunli Xu, Sylvie M. Guichard
Publikováno v:
Targeted Oncology. 18:269-285
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b83a4b5ffa700d6591f630c62f30ad00
https://doi.org/10.1007/s11523-023-00949-7
https://doi.org/10.1007/s11523-023-00949-7
Autor:
Linda Battalagine, Shawn Schiller, Angela V. Toms, Ping Li, Lili Yao, Maureen Caligiuri, Grace L. Williams, Jennifer Castro, Sylvie Guichard, Kristina R Muskiewicz, Erik Wilker, Eneida Pardo, Kenneth W. Wood, Bradford Graves
Publikováno v:
Cancer Research. 80:3079-3079
Triple negative breast cancer (TNBC) remains a high unmet medical need, commonly treated with chemotherapies. Biomarker-driven treatment strategies have led to the recent approvals of both PARP inhibitors and an immune checkpoint inhibitor for a subs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e3adb57729a88fc4485b22526b7e9c1
https://doi.org/10.1158/1538-7445.am2020-3079
https://doi.org/10.1158/1538-7445.am2020-3079
Autor:
Ensar Halilovic, Robert Schlegel, Jinsheng Liang, John Monahan, Fang Li, Hui Qin Wang, Linda Battalagine, Alan Huang, Z. Alexander Cao
Publikováno v:
Cancer Research. 74:2929-2929
Neuroblastoma is the most common cancer in infancy, accounting for 15% of all childhood cancer-related death. MYCN amplification is the major genetic aberration in high-risk neuroblastoma and is associated with poor outcome. Genome-wide association s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::990239611ec8ea981f806fad295dc1f0
https://doi.org/10.1158/1538-7445.am2014-2929
https://doi.org/10.1158/1538-7445.am2014-2929
Autor:
Shumei Qiu, John Monahan, Joseph D. Growney, Linda Battalagine, Paul W. Manley, Fang Li, Robert Schlegel
Publikováno v:
Molecular Cancer Therapeutics. 12:B65-B65
Activating mutations in either KIT or PDGFR are present in approximately 90% of gastrointestinal stromal tumors (GISTs). Treatment with the KIT and PDGFR inhibitor imatinib can control advanced disease in about 80% of GIST patients. However, the bene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10983e4ee9196b9204d71f5c2575b737
https://doi.org/10.1158/1535-7163.targ-13-b65
https://doi.org/10.1158/1535-7163.targ-13-b65
Abstract 1620: Dovitinib has anti-tumor activity in gastrointestinal stromal tumor (GIST) cell lines
Autor:
Fang Li, Bella O. Gorbatcheva, Shumei Qiu, Paul W. Manley, Matthew Squires, Linda Battalagine, Alex Cao, Juergen Mestan, Joseph D. Growney, John Monahan
Publikováno v:
Cancer Research. 73:1620-1620
Background: Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal tract sarcoma, with 5000-6000 cases per year diagnosed in the United States. Most GISTs carry activating mutations in KIT (≈ 75% of cases) or PDGFR alpha (10%-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8896422901f84fff8d18d6c53e89727f
https://doi.org/10.1158/1538-7445.am2013-1620
https://doi.org/10.1158/1538-7445.am2013-1620
Publikováno v:
Cancer Research. 72:2239-2239
Gastrointestinal stromal tumors (GIST) are the most common type of sarcoma found in the gastrointestinal tract, with 5,000-6,000 cases per year diagnosed in the United States. Activating mutations in KIT, or occasionally in PDGFR are present in up to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::611fde93e947bf6ee5b45a318102cc2d
https://doi.org/10.1158/1538-7445.am2012-2239
https://doi.org/10.1158/1538-7445.am2012-2239